IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

Collaborate with COVID-19 research Make a donation


  • Immunoglobulin clinical trial launched to prevent COVID-19 side effects


    The Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, the University of California-Davis and the University of Texas have launched a clinical trial to analyse how useful a food supplement can be for preventing the worst side effects of COVID-19. The study is looking at bovine-derived immunoglobulins, which have been shown in animal models to reduce the inflammation caused by infection, progression to more severe forms of the disease, and post-COVID syndrome. The first patients participating in the Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People with COVID19 (PICNIC Study) are already taking two daily doses of this supplement.

    Dr Robert Güerri, principal investigator in the trial, member of the Infectious Pathology and Antimicrobial Research Group at the IMIM-Hospital del Mar, and section head of the Infectious Diseases Service at Hospital del Mar, explains that "The aim of the treatment is to sequester and help eliminate the virus from one of its main reservoirs in the body, the gut."

    Read more sobre "Immunoglobulin clinical trial launched to prevent COVID-19 side effects"

  • Transfer opportunities and service offers
  • Scientific publications
  • Research projects
  • Grants and job bank
  • Clinical Research Unit
  • Info Recerca

Subscribe to our newsletter

Notice: Undefined variable: textprivacitat in /webs/ on line 756

Institut Hospital del Mar d'Investigacions Mèdiques

Dr. Aiguader, 88, 08003 Barcelona
See location on Google Maps
Phone: 93 316 04 00 · Fax: 93 316 04 10